All these findings point to plasma GFAP as a possible specific biomarker for Aβ pathology, allowing for discrimination between AD and non-AD clinical phenotypes, as well as for early diagnosis of AD [90]. The gene discussed is GFAP; the disease is Alzheimer disease.